Correlation between physical markers and psychiatric health in a Portuguese systemic lupus erythematosus cohort: The role of suffering in chronic autoimmune disease

Margarida Figueiredo-Braga¹,², Caleb Cornaby³, Miguel Bernardes⁴, Marta Figueiredo¹, Cristina Dos Santos Mesquita⁶, Lucía Costa⁴, Brian D. Poole³*

¹ Medical Psychology Unit, Dep. Clinical Neurosciences and Mental Health, Faculty of Medicine, University of Porto, Porto, Portugal, ² I3S Instituto de Investigação e Inovação em Saúde, Porto, Portugal, ³ Department of Microbiology and Molecular Biology, Brigham Young University, Provo, Utah, United States of America, ⁴ Rheumatology Department, Hospital de São João EPE, Porto, Portugal, ⁵ Departamento de Psicologia Aplicada (DPA), Universidade do Minho, Minho, Portugal

* bpoole@gmail.com

Abstract

Background
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects a large number of people throughout the world. Anxiety, depression and fatigue are common symptoms of SLE that substantially contribute to decreased quality of life. This study investigates the interplay between physical and psychiatric manifestations of lupus. To this end, an SLE patient cohort was examined for correlations between clinical presentation, laboratory tests, and psychological indicators.

Methods
Seventy-two lupus patients were evaluated for psychological status using a battery of instruments, including assessments for fatigue (CFS & FSS), depression (HADS), anxiety (HADS), overall health (SF-36 & PSQI) and intimate relationship satisfaction (RAS & CSI). Scores from these assessments were correlated with lupus clinical profiles and laboratory test values.

Results
The prevalence of depression in the SLE patient cohort was 41.7%, as measured by the hospital depression and anxiety scale. The study identified that pain (p = 0.001), body mass index (p = 0.026), Chalder’s fatigue scale (p < 0.001), fatigue severity scale (p < 0.001), and anxiety (p = 0.001) are all positively correlated with depression in SLE patients. Total complement (CH50) (p = 0.032), and SF-36 physical and mental characteristic assessments are negatively correlated with depression. Longitudinal analysis indicated that the disease related complaint alopecia (p = 0.008) and relationship assessment scale scores (p = 0.004) may also be correlated to depression in SLE patients. Multivariate scrutiny of the clinical and...
psychosocial characteristics identified the fatigue severity scale \( (p = 0.026) \), SF-36 physical function \( (p = 0.040) \), physical role function \( (p = 0.030) \), and mental health \( (p = 0.002) \) as the best indicators directly correlated with depression for the SLE cohort.

**Conclusion**

These results reveal the influence of physical manifestations of lupus including fatigue, pain, body mass index and anxiety, as well as decreased physical and mental function, on depression. Fatigue is the strongest factor correlated with depression in SLE patients in the cohort. Both physical and social/psychological aspects likely contribute to the depression and anxiety in lupus.

**Introduction**

Systemic Lupus Erythematosus (SLE) is an autoimmune disease that can affect a wide variety of organ systems. Symptoms vary and can include fever, arthritis, fatigue, weight loss, lymphadenopathy, a characteristic “butterfly rash”, renal disease and cytopenia, in a pleomorphic clinical presentation. Young women are predominantly affected by lupus, which brings significant costs into their personal, family and professional lives. Depression and fatigue are very common, early symptoms of lupus that are major contributors to diminished quality of life [1,2]. [3,4] These psychiatric symptoms are influenced by a variety of factors, and so understanding the causes, interactions, and consequences of depression and anxiety in lupus is a complicated and difficult problem. Factors that may influence depression and anxiety in lupus include culture, social and environmental factors, age, sex, disease activity and disease severity [5].

Both physical and psychological symptoms of lupus can affect the patient’s life. These could include such effects as weight and activity changes, fatigue and sleep disturbances. Moreover, a depressive disorder must be differentiated from more transient depressive symptoms[6]. Examination of the quality of depression, in addition to its prevalence, might yield more clues to the underlying mechanisms[7].

Due in large part to this complexity, the causes of depression in lupus are not clear. Biological mechanisms have been implicated because depression in lupus is associated with other CNS diseases, higher disease activity and more severe clinical manifestations[8,9]. Brain inflammation, interaction of auto-antibodies with antigens on neuronal cells membrane, and cytokine expression triggering neurotransmitter dysfunction have been regarded as possible causes of depression in SLE patients and in rodent SLE models[10–15].

Fatigue and pain are common symptoms in SLE, affecting up to 90% of the patients, who rate these symptoms as severe manifestations of the disease[16–18]. Neither clinical markers of disease activity nor medication (often used as a proxy indicator for disease severity) correlate well with levels of pain and fatigue[19]. Treatment of SLE may be substantially enhanced by better understanding fatigue and depression and their associations with immune activation [20].

The purpose of this study is to examine the diverse array of social, physical, and psychiatric factors that are interrelated with depression in lupus. We hypothesize that some of these features of lupus will correlate well with depression, and that these could aid clinicians in identifying and treating the depression and anxiety associated with lupus. We further hypothesize that
some inflammatory or physical indicators of disease activity will be associated with psychological symptoms.

**Methods**

**Patients**

The studied population included 72 Caucasian lupus patients and 34 controls, recruited in northern Portugal. All SLE patients were previously diagnosed and followed at an outpatient unit. Diagnosis was established according to the American College of Rheumatology Criteria (ACR) guidelines and the duration of the disease was measured from the time when the patients first met the diagnostic criteria. The control group of patients with depression but without SLE was undergoing treatment at a private psychiatric clinic at the time of the study. The response rate for this group was 76%.

To account for inter-interviewer variation, psychiatric evaluation and psychometric markers were tested by one psychiatrist and one psychologist to establish the severity of depression. Exclusion criteria comprised history of substance abuse, personality disorders and other major psychopathology than depression. Patients and controls were subsequently interviewed by phone by trained interviewers. The literature corroborates phone interviews as valid and precise tools for psychological data collection[21–23].

Participants’ socio-demographic data included age, educational level, employment status (active/non-active) and marital status (Table 1). Laboratory and SLE clinical evaluations were obtained for the SLE patients through the clinical records. Lab tests included leukocytes (10⁹/L), lymphocytes (percentage), neutrophils (percentage), platelets (10⁹/L), erythrocyte sedimentation rate (mm/h), anti-dsDNA antibody titer (IU/ml), C3 level (g/L), C4 level (g/L), CH50 level (U/ml), and C-reactive protein level (mg/dl). Other clinical symptomology also recorded from patients included cutaneous manifestations, photosensitivity, foot and mouth ulcers, arthritis, alopecia, headaches, kidney disease, neurological symptoms, pulmonary disease, musculoskeletal pathology, history of hypertension, and acute confusion syndrome (ACS). Smoking and alcohol consumption were also recorded.

The study was submitted and approved by the Ethical Committee of the São João Hospital IRB (EPE) in accordance with the Declaration of Helsinki. All participants gave written informed consent.

**Psychosocial evaluation**

Socio-demographic characterization included age, education measured as years of school, marital status and socio-economic class evaluation. Psychological evaluations were obtained through a battery of standardized instruments.

**Fatigue Severity Scale (FSS).** The short form of the FSS allows evaluation of self-reported fatigue[24]. The Portuguese version includes nine items and is recommended as the instrument of choice for research purposes in studies involving patients diagnosed with SLE[5].

The FSS demonstrates good psychometric properties (Cronbach’s $\alpha = 0.89$ and test-retest reliability 0.84). A final score is obtained from the mean of all scored items, with higher scores revealing higher severity of fatigue. Presence of clinical levels of fatigue was defined by a FSS score $>3$. The scale has proved to be sensitive to change and reliable for telephone interviewing.

**Hospital Anxiety and Depression Scale (HADS).** The Hospital Anxiety and Depression Scale (HADS) is a self-rating scale with good psychometric properties (Cronbach’s alpha coefficients of 0.94), designed to measure anxiety and depression in physically ill individuals[25]. Translated and adapted for Portugal[26,27], it is subdivided in two subscales of 7 items that
measure independently anxiety and depression. The partial result of each scale varies between 0 and 21. Scores ranging from 8 to 10 are considered mild, from 11 to 14 moderate and 15 to 21 severe[28] and the authors suggest 8 as the cutoff point, considering values below as indicating the absence of anxiety and depression[25]. It is important to note that the scale is indicative of depressive symptoms in the last week, and not necessarily clinical depression.

**Pittsburgh Sleep Quality Index (PSQI).** This instrument presents good psychometric properties, with high reliability (Cronbach’s alpha = 0.83) and validity. The seven components evaluated—sleep latency, sleep disturbances, sleep duration, sleep quality, sleep efficiency, use of sleep medications and daytime dysfunction allow the gathering of a global score varying from 0 to 21[29,30]. The PSQI is reliable for sleep quality assessment in telephone interviews and permits the identification of poor sleepers (score > 5)[31,32].

**Chalder Fatigue Scale (CFS).** The Chalder Fatigue Scale[33], is an instrument with 11 items that evaluates the extent and severity of mental and physical fatigue using a five-point scale. Higher scores indicate higher fatigue.

**Medical outcomes study questionnaire short form 36 health survey (SF-36).** The SF-36[34], Portuguese version[26], is a 36 item questionnaire that measures functional health and well-being in eight domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, mental health and reported health transition. The

Table 1. Sociodemographic Characteristics of the patient cohort.

| Characteristics | All Subjects | SLE Subjects | SLE, non-depressed (HADS Depression ≤ 7) | SLE, depressed (HADS Depression ≥ 8) | p-value | p-value | p-value | p-value |
|-----------------|--------------|--------------|-----------------------------------------|--------------------------------------|---------|---------|---------|---------|
|                 | (N = 106)    | (N = 72)     | (N = 42)                                 | (N = 30)                             |         |         |         |         |
| Gender, no. (%) | Female       | 103 (97)     | 72 (100)                                 | 42 (100)                             | 30 (100) | 31 (91) |
| Age, mean ± SD  | 46.64 ± 11.49| 44.31 ± 9.9 | 41.55 ± 8.51                            | 48.17 ± 10.53                        | 0.004 a | 51.59 ± 13.12 | 0.006 d | < 0.001 d | 0.259 a |
| Education (years), mean ± SD | 8.80 ± 3.80 | 8.8 ± 3.6 | 9.8 ± 3.18 | 7.43 ± 3.73 | 0.005 a | 8.79 ± 4.26 | 0.991 a | 0.244 a | 0.182 a |
| Education Level, no. (%) | 0.006 b | 0.142 b | 0.083 b | 0.870 b |
| Primary         | 38 (36)      | 26 (36)      | 8 (19)                                  | 18 (60)                              | 11 (32) |
| Middle School   | 24 (23)      | 16 (22.2)    | 12 (28.6)                               | 4 (13.3)                             | 8 (24)  |
| High School     | 25 (24)      | 20 (27.8)    | 15 (35.7)                               | 5 (16.7)                             | 5 (15)  |
| College         | 19 (17)      | 9 (12.5)     | 6 (14.3)                                | 3 (10)                               | 10 (29) |
| Marriage Status, no. (%) | 0.667 b | 0.070 b | 0.214 b | 0.161 b |
| Unmarried       | 16 (15)      | 11 (15.3)    | 8 (19.0)                                | 3 (10)                               | 6 (18)  |
| Married         | 78 (74)      | 53 (73.6)    | 30 (71.4)                               | 23 (76.7)                            | 25 (74) |
| Divorced        | 9 (8)        | 8 (11.1)     | 4 (9.5)                                 | 4 (13.3)                             | 1 (3)   |
| Widowed         | 3 (3)        | 0 (0)        | 0 (0)                                   | 0 (0)                                | 3 (9)   |
| Employment Status, no. (%) | 0.088 b | 0.300 b | 1.000 b | 0.074 b |
| Employed        | 59 (56)      | 28 (38.9)    | 20 (47.6)                               | 8 (26.7)                             | 17 (50) |

*Independent samples t-test; ^ Fisher’s exact chi-squared test; d Welch’s t-test

https://doi.org/10.1371/journal.pone.0195579.t001
instrument allows a score for each domain, as well as a global score. Higher scores indicate better health.

**Couples Satisfaction Index (CSI).** The CSI[35] (Portuguese experimental version from Barbosa & Figueiredo-Braga, 2014) is a 32 item questionnaire that measures couple satisfaction in the relationship. Higher scores indicate greater satisfaction.

**Relationship Assessment Scale (RAS).** The RAS[36] (Portuguese experimental version from Mesquita, Barbosa, & Figueiredo-Braga, 2014) is a 7 item instrument, with a five-point scale that measures general satisfaction with the relationship.

**Statistical analysis**

Differences in the demographic, clinical, and psychological variables between the total SLE subjects, SLE non-depressed (LN), SLE depressed (LD), and depressed control (DC) subjects were determined using the independent t-test, Fisher’s exact chi-squared, Mann-Whitney U, Wilcoxon rank sum, or Welch’s tests when appropriate. Fisher’s exact chi-squared was used in place of the standard chi-squared test, which would typically be utilized, due to the smaller sample size of the groups compared. The statistical test used for the comparisons are indicated in the table legends. Multivariant analysis was performed using a generalized linear model. The best fit model was determined using the model with the appropriate number of variables (less than or equal to 8 variables) and the highest pseudo \( R^2 \) value with the lowest approximate Akaike information criterion (AICc) value. In the multivariate analysis, the HADS depression score for all SLE subjects was used as the dependent variable and all candidate models included the confounding variables of age, education in years (socioeconomic status indicator), and body mass index. Statistical analysis was performed using the statistical software R and SPSS (IBM). An alpha value less than or equal to 0.05 was considered significant.

**Results**

The systemic lupus erythematosus (SLE) patient cohort consisted of 72 females with a mean age of 44.31 years. 41.7% of SLE patients demonstrated pathological HADS depression scores, indicating current depressive symptoms. This prevalence, while high, is not uncommonly so for SLE populations[37,38].

A cohort of 34 physically healthy people who were diagnosed and being treated for depression acted as a control group (Hereafter referred to as DC, depressed control). This group was slightly older than the lupus cohort with a mean age of 57.69 years. For several analyses the SLE cohort was divided into two groups, those who demonstrated normal HADS depression scores (HADS < 8, n = 42, referred to as LN, Lupus non-depressed) and those who recorded above normal HADS depression scores (HADS ≥ 8 n = 30, referred to as LD, lupus depressed). To ensure that the DC group was comparable with the LD group, despite the selection of the lupus depression group by HADS score, the depressed non-lupus group was also stratified by depression, and only the depressed patients with HADS scores of ≥8 were compared to the lupus depression group. This selection still significantly demonstrated the same patterns that were observed using the entire depressed patient cohort.

The LD group displayed fewer years of formal education compared to the LN group (p = 0.005). When years of education are compared between LN patients and the DC group, the DC group has significantly fewer (p = 0.018), but there is no significant difference between the LD patients and DC patients (p = 0.871) (Table 1). Aside from years of education, the SLE cohort sub groups and the depressed patient control cohort share similar socioeconomic indicators such as marital and employment status.
Clinical manifestations

The laboratory data were similar between the LD and LN groups save for the total complement (CH50) levels. These levels are significantly lower on average in the LD patients, who had a mean CH50 level of 9.81 (± 39.07) U/ml compared to the LN group that had a mean CH50 level of 45.88 (± 86.24) U/ml. This large difference is statistically significant (p = 0.032) (Table 2).

Table 2. SLE study cohort clinical characteristics.

| Characteristics | SLE Subjects (N = 72) | SLE, non-depressed (HADS Depression < 8) | SLE, depressed (HADS Depression ≥ 8) | SLE, non-depressed to SLE, depressed |
|-----------------|-----------------------|------------------------------------------|--------------------------------------|-----------------------------------|
| Disease Duration| 15.11 ± 8.47          | 14.57 ± 7.27                            | 15.87 ± 9.99                        | 0.526 a                           |
| Body Mass Index | 24.55 ± 5.64          | 23.16 ± 3.63                            | 26.49 ± 7.24                        | 0.026 d                           |
| Pain Score      | 5.5                   | 4                                        | 7.5                                  | 0.001 c                           |

| Laboratory Results                                                                 |
|-------------------------------------------------------------------------------------|
| Leukocytes (10^9/L)                                                                 |
| 6.77 ± 2.15                                                                       | 6.88 ± 2.36                            | 6.62 ± 1.85                          | 0.514 a                           |
| Lymphocytes (%)                                                                    |
| 28.98 ± 8.11                                                                       | 29.58 ± 8.37                           | 28.14 ± 7.81                         | 0.443 a                           |
| Neutrophils (%)                                                                    |
| 58.78 ± 7.10                                                                       | 58.43 ± 7.53                           | 59.27 ± 8.49                         | 0.665 a                           |
| Platelets (10^9/L)                                                                 |
| 228.64 ± 82.33                                                                    | 217.06 ± 90.42                         | 244.62 ± 67.92                       | 0.172 a                           |
| Sedimentation Velocity (mm/h)                                                     |
| 22.67 ± 20.04                                                                      | 22.84 ± 21.49                          | 22.43 ± 18.25                        | 0.935 a                           |
| Anti-dsDNA (IU/ml)                                                                 |
| 99.89 ± 111.73                                                                    | 99.63 ± 116.53                         | 100.30 ± 106.28                     | 0.983 a                           |
| C3 (g/L)                                                                           |
| 44.23 ± 55.19                                                                      | 42.11 ± 53.4                           | 47.17 ± 58.38                        | 0.710 a                            |
| C4 (g/L)                                                                           |
| 8.67 ± 11.36                                                                      | 8.49 ± 10.71                           | 8.9 ± 12.38                          | 0.881 a                            |
| CH50 (U/ml)                                                                        |
| 32.05 ± 73.63                                                                      | 45.88 ± 86.24                          | 9.81 ± 39.07                         | 0.032 d                            |
| C-Reactive Protein (mg/dl)                                                         |
| 0.43 ± 0.58                                                                        | 0.37 ± 0.6                             | 0.49 ± 0.53                          | 0.453 a                            |

| Clinical Symptomology                                                             |
|------------------------------------------------------------------------------------|
| Cutaneous Manifestations(%)                                                        |
| 37 (51.4)                                                                           | 18 (42.9)                              | 19 (63.8)                             | 2.30 (0.88–6.03)                   | 0.100 b                           |
| Photosensitivity, no. (%)                                                          |
| 65 (90.3)                                                                           | 36 (85.7)                              | 29 (96.7)                             | 4.83 (0.55–42.45)                  | 0.227 b                           |
| Foot & Mouth Ulcers, no. (%)                                                       |
| 28 (38.9)                                                                           | 14 (33.3)                              | 14 (46.7)                             | 1.75 (0.67–4.58)                   | 0.328 b                           |
| Arthritis, no. (%)                                                                 |
| 60 (83.3)                                                                           | 32 (76.2)                              | 28 (93.3)                             | 1.89 (0.34–10.48)                  | 0.063 b                           |
| Alopecia, no. (%)                                                                  |
| 48 (66.7)                                                                           | 29 (69)                                | 19 (63.3)                             | 0.77 (0.29–2.08)                   | 0.623 b                           |
| Headaches, no. (%)                                                                 |
| 40 (55.6)                                                                           | 17 (40.5)                              | 23 (76.7)                             | 4.83 (1.70–13.76)                  | 0.004 b                           |
| Kidney Disease, no (%)                                                             |
| 39 (54.2)                                                                           | 22 (52.4)                              | 17 (56.7)                             | 1.19 (0.46–3.05)                   | 0.812 b                           |
| Neurological Symptoms (%)                                                          |
| 19 (26.4)                                                                           | 9 (21.4)                               | 10 (33.3)                             | 1.83 (0.63–5.28)                   | 0.289 b                           |
| Smoke, no. (%)                                                                     |
| 13 (18.1)                                                                           | 9 (21.4)                               | 4 (13.3)                              | 0.56 (0.16–2.04)                   | 0.537 b                           |
| Alcohol, no. (%)                                                                   |
| 6 (8.3)                                                                             | 3 (7.1)                                | 3 (10)                                | 1.44 (0.27–7.70)                   | 0.688 b                           |
| Neuropsychiatric pathology (%)                                                     |
| 19 (26.4)                                                                           | 9 (21.4)                               | 10 (33.3)                             | 1.83 (0.63–5.28)                   | 0.298 b                           |
| Pulmonary disease, no. (%)                                                         |
| 19 (26.4)                                                                           | 10 (23.8)                              | 9 (30)                                | 1.37 (0.48–3.94)                   | 0.596 b                           |
| Musculoskeletal Pathology (%)                                                      |
| 11 (15.3)                                                                           | 6 (14.3)                               | 5 (16.7)                              | 1.2 (0.33–4.37)                    | 1.000 b                           |
| Physically Active, no. (%)                                                         |
| 24 (33.3)                                                                           | 17 (40.5)                              | 7 (23.3)                              | 0.45 (0.16–1.27)                   | 0.204 b                           |
| Thyroid Pathology, no. (%)                                                         |
| 5 (6.9)                                                                             | 3 (7.1)                                | 2 (6.7)                               | 0.93 (0.15–5.93)                   | 1.000 b                           |
| History of Hypertension (%)                                                        |
| 17 (23.6)                                                                           | 9 (21.4)                               | 8 (26.7)                              | 1.33 (0.45–3.98)                   | 1.000 b                           |
| Acute Confusion Syndrome, (%)                                                     |
| 3 (4.2)                                                                             | 2 (4.8)                                | 1 (3.3)                               | 0.69 (0.06–7.97)                   | 1.000 b                           |

* Independent samples t-test;  
* Fisher’s exact chi-squared test;  
* Mann-Whitney U test;  
* Welch’s t-test

https://doi.org/10.1371/journal.pone.0195579.t002
The LD patients reported higher pain scores than the LN subjects (p = 0.001). The LD group recorded a median pain score of 7.5, compared to 4 for the LN group. As HADS depression scores increase, the pain scores also increase, showing significant correlation (Fig 1, p < 0.001). Along with the increase in pain, the LD patients further reported a higher frequency of headaches (p = 0.004) with 76.7% compared to 40.5% of the LN patients (Table 2).

An increase in body mass index (BMI) was observed in the LD cohort compared to the LN group (p = 0.026). LN subjects had a mean BMI of 23.16 (± 3.63) compared to 26.49 (± 7.24) in the LD group (Table 2). The DC group had a mean BMI of 25.41 (± 4.78). Interestingly, both the LD and DC groups have significantly higher BMIs than the LN group (p = 0.025). There was a higher percentage of subjects from the LD group that regularly consumed alcoholic beverages compared to either SLE group, with 32% compared 10% and 7.1%, for the LD and LN subjects respectively (p = 0.007 and p = 0.038).

**Psychosocial function**

Both psychological tools used to assess fatigue severity demonstrated significantly different levels of fatigue between the LD and the LN patients (Table 3). Lower scores on the CFS indicate less fatigue, while higher scores indicate more fatigue. The LN subjects had less physical, mental, and overall fatigue than the LD patients (p = 0.001, p = 0.001, p < 0.001, respectively). The depression-only group CFS scores are not statistically different from either group.

The second fatigue assessment, the fatigue severity scale (FSS), also found statistical differences in fatigue between the LD and LN groups (p < 0.001). The LN group demonstrated a mean FSS score of 4.12 (± 1.65) compared to the LD group (5.59 ± 0.85). Interestingly, the Lupus patients as a whole had significantly higher levels of fatigue compared to the DC group (p = 0.002). The LD group also had significantly higher fatigue than the DC group (P < 0.0001), but the LN group did not (p < 0.0001) (Table 4).

To assess the patients’ perception of their general health, the SF-36 assessment was used. This psychological tool yields eight sub scores, each of which was different between the LD and LN subjects. The SF-36 assessment gives a higher score for patients that feel healthier in that sub category, with lower scores indicating lower health. The LN cohort reported a median physical function score of 24, and a median physical role function score of 14. The LD patients demonstrated significantly lower physical function and physical role function scores, with median scores of 17.5 and 9.5 respectively (p < 0.001 and p = 0.001, respectively) (Table 3). The LN patients exhibited a mean general health score of 13.32 ± 3.44 and a median health
transition score of 3, which was significantly higher than the LD, (general health 10.97 ± 2.46, health transition 4), (p = 0.002 and p = 0.001, respectively). The final sub score for physical health, bodily pain, in the LN cohort was had a mean of 7.43 ± 2.93, while the LD group had a mean of 4.75 ± 1.87. This difference in scores indicates a significantly higher level of perceived pain in the SLE depressed subjects (p < 0.001) (Table 3).

The mental health assessment portion of the SF-36 consists of the variable sub scores including vitality, social role function, emotional role function, and mental health. LN patients exhibited higher vitality and social role function scores (p < 0.001 and p < 0.001, respectively) with a median score of 11 and 8 respectively, than the LD patients, which had a median score of 7.5 and 6, respectively. Emotional health assessed by the SF-36 recorded that the LN subjects had a median score of 11, while the LD patients had a lower median score of 7.5 (p < 0.001). The final sub score calculated for the LN cohort, mental health, had a median score of 16.5 and the LD patients had a median score of 13 (p < 0.001).

Table 3. SLE patient psychological characteristics.

| Characteristics | SLE Subjects (N = 72) | SLE, non-depressed (HADS Depression ≤ 7) (N = 42) | SLE, depressed (HADS Depression ≥ 8) (N = 30) | SLE, non-depressed to SLE, depressed | Odds Ratio (95% CI) | p-value |
|-----------------|-----------------------|--------------------------------------------------|-----------------------------------------------|--------------------------------------|---------------------|---------|
| Chalder Fatigue Scale, median | 16 | 14 | 18 | 0.001 c |
| Physical Score | 10 | 9 | 12 | 0.001 c |
| Mental Score | 5 | 5 | 7 | 0.001 c |
| SF-36 Scores | | | | | |
| Physical Function, Median | 22 | 24 | 17.5 | < 0.001 c |
| physical Role Function, Median | 11.5 | 14 | 9.5 | 0.001 c |
| Emotional Role Function, Median | 9 | 11 | 7.5 | < 0.001 c |
| General Health, mean ± SD | 12.34 ± 3.27 | 13.32 ± 3.44 | 10.97 ± 2.46 | 0.002 a |
| Change of Health, Median | 3 | 3 | 4 | 0.001 c |
| Social Role Function, Median | 7 | 8 | 6 | < 0.001 c |
| Bodily Pain | 6.32 ± 2.86 | 7.43 ± 2.93 | 4.75 ± 1.87 | < 0.001 d |
| Vitality, Median | 10 | 11 | 7.5 | < 0.001 c |
| Mental Health, Median | 14.5 | 16.5 | 13 | < 0.001 c |
| HADS Anxiety | 9.31 ± 3.86 | 8.05 ± 3.75 | 11.07 ± 3.32 | 0.001 a |
| HADS Anxiety Groups, no. (%) | | | | 0.001 b |
| normal (HADS ≤ 7) | 23 (31.9) | 20 (47.6) | 3 (10) | 0.12 (0.03–0.47) |
| mild to severe (HADS ≥ 8) | 49 (68.1) | 22 (52.4) | 27 (90) | 8.18 (2.15–31.18) |
| Pittsburg Sleep Quality Index | 8 | 8 | 9 | 0.076 c |
| Pittsburg Sleep Quality Index groups (%) | | | | 1.000 b |
| normal (PSQI ≤ 5) | 10 (13.9) | 6 (14.3) | 4 (13.3) | 0.92 (0.24–3.60) |
| poor (PSQI ≥ 6) | 62 (86.1) | 36 (85.7) | 26 (86.7) | 1.08 (0.28–4.23) |
| Couple Satisfaction Index | 1479.83 ± 668.26 | 1551.85 ± 680.78 | 1374.35 ± 647.07 | 0.282 a |
| Relationship Assessment Scale | 25.45 ± 4.19 | 25.48 ± 3.95 | 25.40 ± 4.56 | 0.869 c |
| Fatigue Severity Scale | 4.73 ± 1.55 | 4.12 ± 1.65 | 5.59 ± 0.85 | < 0.001 a |

* Independent samples t-test;  
† Fisher’s exact chi-squared test;  
‡ Mann-Whitney U test;  
§ Welch’s t-test  
HADS: Hospital Anxiety and Depression Scale; PSQI: Pittsburg Sleep Quality Index  
https://doi.org/10.1371/journal.pone.0195579.t003
Table 4. Study cohort psychological characteristics.

| Characteristics                      | SLE Subjects | SLE, non-depressed (HADS Depression ≤ 7) | SLE, depressed (HADS Depression ≥ 8) | SLE, non-depressed to SLE, depressed | SLE Subjects to Depressed | SLE, non-depressed to SLE, depressed | SLE, depressed to Depressed |
|--------------------------------------|--------------|------------------------------------------|--------------------------------------|--------------------------------------|--------------------------|--------------------------------------|----------------------------------|
|                                      | (N = 72)     | (N = 42)                                  | (N = 30)                             | Odds Ratio (95% CI)                  | p-value                  | Odds Ratio (95% CI)                  | p-value                          |
| Disease Duration (years), mean ± SD  | 15.11 ± 8.47 | 14.57 ± 7.27                             | 15.87 ± 9.99                         | 0.526 a                             | N/A                      | N/A                                  | N/A                             |
| BMI, mean ± SD                       | 24.55 ± 5.64 | 23.16 ± 3.63                             | 26.49 ± 7.24                         | 0.026 d                             | 25.41 ± 4.78             | 0.443 a                              | 0.023 a                          |
| Pain Score, median                   | 5.5          | 4                                        | 7.5                                  | 0.001 c                             | 5                        | 0.333 c                              | 0.017 c                          |
| Smoking—no. (%)                      | Yes          | 13 (18.1)                                | 9 (21.4)                             | 0.56 (0.16–2.04)                    | 2 (6)                    | 0.688 b                              | 0.003 b                          |
| Alcohol—no. (%)                      | Yes          | 6 (8.3)                                  | 3 (7.1)                              | 1.44 (0.27–7.70)                    | 11 (32)                  | 0.001 b                              | 0.237 a                          |
| Physically Active—no. (%)            | Yes          | 24 (33.3)                                | 17 (40.5)                            | 0.204 b                             | 0.291 b                  | 0.817 b                              | 0.114 b                          |
| HADS Anxiety, mean ± SD              | 9.31 ± 3.86  | 8.05 ± 3.75                              | 11.07 ± 3.32                         | 0.001 a                             | 9.15 ± 4.26              | 0.855 a                              | 0.237 a                          |
| HADS Anxiety Groups, no. (%)         | normal (HADS ≤ 7) | 23 (31.9)                           | 20 (47.6)                            | 0.12 (0.03–0.47)                    | 0.12 (0.03–0.27)        | 0.279 b                              | 0.005 b                          |
|                                      | mild to severe (HADS ≥ 8) | 49 (68.1)                           | 22 (52.4)                            | 8.18 (2.15–31.18)                   | 0.14 (0.04–0.55)        | 0.38 b                               | 0.110 b                          |
| Pittsburgh Sleep Quality Index, median | 8          | 8                                        | 9                                    | 0.076 c                             | 7.5                      | 0.075 c                              | 0.360 c                          |
| Pittsburgh Sleep Quality Index groups, no. (%) | normal (PSQI ≤ 5) | 10 (13.9)                           | 6 (14.3)                             | 0.92 (0.24–3.60)                    | 10 (29)                  | 0.39 (0.14–1.05)                     | 0.37 (0.10–1.34)                 |
|                                      | poor (PSQI ≥ 6) | 62 (86.1)                           | 36 (85.7)                            | 1.08 (0.28–4.23)                    | 24 (71)                  | 2.58 (0.95–7.79)                     | 2.71 (0.75–9.79)                 |
| Relationship Assessment Scale, mean ± SD | 25.45 ± 4.19 | 25.48 ± 3.95                          | 25.40 ± 4.56                         | 0.869 c                             | 21.32 ± 6.44             | 0.009 d                              | 0.014 d                          |
| Fatigue Severity Scale, mean ± SD    | 4.73 ± 1.55  | 4.12 ± 1.65                              | 5.59 ± 0.85                          | < 0.001 a                           | 3.72 ± 1.63              | 0.002 a                              | 0.224 a                          |

* Independent samples t-test;  
* Fisher’s exact chi-squared test;  
* Mann-Whitney U test;  
* Welch’s t-test  

https://doi.org/10.1371/journal.pone.0195579.t004
The LD patients were highly anxious, with 90% demonstrating heightened anxiety scores compared to the LN subjects, who had 52.4% with HADS anxiety scores indicating above normal anxiety (p = 0.001). The DC cohort exhibited similar anxiety scores to the SLE non-depressed control with 56% of the subjects having higher than normal anxiety scores. These values are significantly lower than those observed in the SLE depressed patients (p < 0.001).

**Longitudinal impact**

Approximately one month after the initial clinical and psychosocial assessment, patients from the SLE cohort were reassessed. Of thirty SLE patients that exhibited pathological HADS depression scores, five of them had normal HADS depression scores during this second assessment. While five patients compose a rather small group, these differences might spark further studies. In the first assessment, every one of these patients exhibited alopecia as a disease related complaint, however, in the second assessment, all five no longer had alopecia (p = 0.008). A further difference identified was the strong increase in relationship assessment scale (RAS) scores (p = 0.004). The first assessment revealed a mean relationship assessment scale score of 22.40 ± 1.52, while the second assessment recorded a mean relationship assessment scale score of 30.60 ± 2.79 (Fig 2).

**Multivariate analysis**

To determine what variables might play a role as the best indicators of increased HADS depression scores in the LD relative to the LN groups, we utilized generalized linear regression models for the multivariate analysis. A list of candidate models was compiled and compared to one another based on the number of variables included, pseudo R$^2$, and AICc values. Each model included the confounding sociodemographic variables that were identified as significantly different between the LD and LN subjects, namely age, body mass index, and years of education. All other variables that were found to be significantly different between the LN and LD patients were included as possible variables in the multivariant analysis. The only significant variable not included as a candidate variable was HADS anxiety scores. This variable was omitted due to the close correlation with the HADS depression score and because they are derived from the same assessment. The best fit model identifies the best indicators of depression for this SLE cohort. Of the variables included in the model, several were considered significant. These include three SF-36 scores, physical function (p = 0.040), physical role function (p = 0.030), and mental health (p = 0.002), as well as fatigue severity scale scores (p = 0.029). Of these, the latter is likely the most sensitive to changes in HADS depression scores as indicated by the odds ratio of 1.11 (1.01–1.22), which is slightly higher than other significant variables (Table 5).

**Discussion**

The overwhelming finding of this study is that lupus patients with depression are experiencing extreme suffering. They have a higher number of depressive symptoms even than patients for whom depression is the primary diagnosis. They are also more prone to experience anxiety. In addition to being more depressed and anxious than primary depression patients, they suffer more physical symptoms than lupus patients without depression. These depressed lupus patients are living in the worst of both worlds.

Of the variables examined in this study, fatigue was the strongest indicator for depression in the lupus patients. This was observed in the univariate analysis, in the Chalder Fatigue Scale and Fatigue Severity Scale, and the multivariate analysis, making the measurement of fatigue an excellent indicator of depression in SLE patients (Table 3). Fatigue has previously been
Five lupus patients who had depressive symptoms at the onset of the study improved their HADS depression scores to the point where they were considered non-depressed. These patients showed concomitant increases in relationship satisfaction, as measured by the Relationship Assessment Scale. \( P = 0.004, N = 5 \).

https://doi.org/10.1371/journal.pone.0195579.g002
correlated to an increased risk for depression among lupus patients[1,39–41], and this study strengthens these associations.

Interestingly, considering the strong association between fatigue and depression, the LD and LN cohorts did not have a significant difference in sleep quality. While the prevalence of poor sleepers is equal to or higher than that observed in the general population, sleep quality does not appear to be correlated with depression, indicating that a poor sleep quality is most likely not causing depressive symptoms, and perhaps is not one of the significant factors contributing to such drastically high levels of fatigue among lupus patients[42]. However, overlapping symptoms may be masking the effects of sleep quality in this population.

Fatigue has been found to correlate with increased body mass index in SLE patients[41]. This study supports this work (Table 2). Increased body mass index scores correlated with increased levels of depression amongst in SLE cohort. These results emphasize the importance of assisting patients alleviate chronic fatigue, as fatigue seems to be associated with a variety of psychosocial and clinical aspects of SLE. The findings from the fatigue assessments demonstrate that the depressed lupus cohort suffers from both physical and mental fatigue. The need for continued research to better understand how to best treat both types of patient fatigue is therefore potentially one of the most important ways to promote lupus patient quality of life.

The SF-36 psychosocial assessments were also excellent indicators of depression for the lupus cohort. All the physical and mental categories were negatively correlated with depression (Table 3). Two of the SF-36 physical components, physical and physical role function, were directly correlated with depression scores in the multivariate analysis. These findings support multiple studies that indicate SF-36 scores are negatively correlated with depression in SLE subjects[1,43]. It has been noted that patients experiencing symptoms of depression may understate their physical and mental functioning, leading to lower scores across the board, such as we observed. However, even if this is the case, these lower scores are still indicative of depression and could be useful in identifying patients in special need of psychiatric care.

Interestingly, the DC group show significantly higher scores in these three categories and most of the other SF-36 categories when compared to the SLE depressed subjects. These results suggest that the SLE depressed patients decreased physical and mental health is likely a result of SLE disease activity as opposed to depression. Another hypothesis could be the cumulative burden of the disability imposed by an autoimmune and a mental disorder severely diminishes quality of life.

Heightened pain correlated with increased depression in this study. This evidence confirms various studies demonstrating that increased pain is related to greater risk for depression in

### Table 5. Multivariate model for SLE cohort.

| Variables               | Odds Ratio (95% CI) | p-value |
|-------------------------|---------------------|---------|
| Age (years)             | 1.01 (0.99–1.02)    | 0.277   |
| Education (years)       | 0.99 (0.96–1.02)    | 0.451   |
| Body Mass Index         | 1.01 (1.00–1.02)    | 0.123   |
| SF-36 Score             |                     |         |
| Physical Function       | 0.97 (0.95–1.00)    | 0.040   |
| Physical Role Function  | 1.04 (1.00–1.07)    | 0.030   |
| Vitality                | 0.97 (0.93–1.01)    | 0.180   |
| Mental Health           | 0.96 (0.93–0.98)    | 0.002   |
| Fatigue Severity Scale  | 1.11 (1.01–1.22)    | 0.029   |
| Model Fit Summary       | pseudo R2           | AICc     |
|                         | 0.787               | 367.720 |

https://doi.org/10.1371/journal.pone.0195579.t005
SLE patients[44,45]. Also of interest is the higher frequency of headaches observed in the LD population compared to the LN patients. A final interesting clinical characteristic is the decreased levels of total complement (CH50) observed in the depressed patients. This supports previously observed changes in complement levels in patients with neuropsychiatric lupus and animal models[44,46,47]. Low complement is a marker of inflammation and disease activity in lupus, and suggests that heightened immune dysfunction and associated disease activity correlates with more depression. Interestingly, other commonly used indicators of disease activity, such as C-reactive protein levels or Sedimentation Rate, do not correlate with depression. These tests also failed to correlate with any lupus symptoms in this cohort.

The lupus patients were re-evaluated a month after their initial enrollment. Five patients who were exhibiting depressive symptoms upon the first evaluation were no longer at the second contact. All of these patients had alopecia on their first contact but it was gone by their second assessment. They also rated their relationships as more satisfying. Increased satisfaction with a close relationship in SLE patients is likely a protective factor resulting in decreased depressive symptoms. Supporting and gratifying relationships are known to alleviate depression associated with other chronic and debilitating diseases[48]. However, with the small sample size and the nature of the experiment, no conclusive directionality can be imposed upon the data.

In the SLE cohort we observed a high prevalence (41.7%) of patients with active depressive symptoms. A still higher proportion of SLE subjects reported above average anxiety scores, 65.9%.

In summary, this cohort provides a comprehensive look into the relationship between depression and clinical and psychosocial variables in lupus. The findings highlight the importance of assisting patients with both physical and mental health care, and identify symptoms and markers that suggest care for depression may be likely. Beyond clinical and laboratory monitoring of immune dysfunction, attentive clinicians are aware of the value of more discrete symptoms as fatigue, pain, anxiety and depression. It has been demonstrated in past studies that treatment of the neuropsychological symptoms improves overall health, and appropriate treatment of physical symptoms assists in the improvement of psychological manifestations [44,49].

### Supporting information

**S1 Dataset.** All data gathered for this study.

(XLSX)

### Acknowledgments

We would like to thank the Fulbright scholar program for funding Dr. Poole.

### Author Contributions

**Conceptualization:** Margarida Figueiredo-Braga, Marta Figueiredo, Cristina Dos Santos Mesquita.

**Data curation:** Margarida Figueiredo-Braga, Marta Figueiredo, Cristina Dos Santos Mesquita, Lúcia Costa, Brian D. Poole.

**Formal analysis:** Margarida Figueiredo-Braga, Caleb Cornaby, Marta Figueiredo, Cristina Dos Santos Mesquita, Brian D. Poole.

**Funding acquisition:** Brian D. Poole.
Investigation: Margarida Figueiredo-Braga, Miguel Bernardes, Marta Figueiredo, Cristina Dos Santos Mesquita, Lúcia Costa, Brian D. Poole.

Methodology: Brian D. Poole.

Project administration: Margarida Figueiredo-Braga, Miguel Bernardes, Brian D. Poole.

Resources: Margarida Figueiredo-Braga, Miguel Bernardes.

Supervision: Margarida Figueiredo-Braga, Brian D. Poole.

Visualization: Caleb Cornaby.

Writing – original draft: Caleb Cornaby.

Writing – review & editing: Margarida Figueiredo-Braga, Brian D. Poole.

References

1. Yilmaz-Onen S, Ilhan B, Can M, Alibaz-Oner F, Polat-Korkmaz O, Ozen G, et al. (2016) Fatigue in systemic lupus erythematosus: Association with disease activity, quality of life and psychosocial factors. Z Rheumatol.

2. Choi ST, Kang Ji, Park IH, Lee YW, Song JS, Park YB, et al. (2012) Subscale analysis of quality of life in patients with systemic lupus erythematosus: association with depression, fatigue, disease activity and damage. Clin Exp Rheumatol 30: 665–672. PMID: 22704691

3. Gao HX, Campbell SR, Cui MH, Zong P, Hee-Hwang J, Gulinello M, et al. (2009) Depression is an early disease manifestation in lupus-prone MRL/lpr mice. J Neuroimmunol 207: 45–56. https://doi.org/10.1016/j.jneuroim.2008.11.010 PMID: 19121871

4. Jorge A, Lertratanakul A, Lee J, Pearce W, McPherson D, Thompson T, et al. (2017) Depression and Progression of Subclinical Cardiovascular Disease in Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken) 69: 5–11.

5. Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria for F (2007) Measurement of fatigue in systemic lupus erythematosus: a systematic review. Arthritis Rheum 57: 1348–1357. https://doi.org/10.1002/art.23113 PMID: 18050225

6. Iverson GL, Woodward TS, Green P (2001) Base rates of WAIS-R VIQ-PIQ differences in 1593 psychiatric inpatients. J Clin Psychol 57: 1579–1587. PMID: 11745599

7. Denburg SD, Carbotte RM, Denburg JA (1997) Psychological aspects of systemic lupus erythematosus: cognitive function, mood, and self-report. J Rheumatol 24: 998–1003. PMID: 9150099

8. Segui J, Ramos-Casals M, Garcia-Carrasco M, de Flores T, Cervera R, Valdes M, et al. (2000) Psychiatric and psychosocial disorders in patients with systemic lupus erythematosus: a longitudinal study of active and inactive stages of the disease. Lupus 9: 584–588. https://doi.org/10.1191/09612030067828730 PMID: 11035432

9. Nery FG, Borba EF, Hatch JP, Soares JC, Bonfa E, Neto FL (2007) Major depressive disorder and disease activity in systemic lupus erythematosus. Compr Psychiatry 48: 14–18. PMID: 17145276

10. Tsai CY, Wu TH, Tsai ST, Chen KH, Thajeb P, Lin WM, et al. (1994) Cerebrospinal fluid interleukin-6, prostaglandin E2 and autoantibodies in patients with neuropsychiatric systemic lupus erythematosus and central nervous system infections. Scand J Rheumatol 23: 57–63. PMID: 8165438

11. Sakic B, Kirkham DL, Balliol DA, Mwanjewe J, Fearon IM, Macri J, et al. (2005) Proliferating brain cells are a target of neurotoxic CSF in systemic autoimmune disease. J Neuroimmunol 169: 68–85. https://doi.org/10.1016/j.jneuroim.2005.06.010 PMID: 16198428

12. Lapteva L, Nowak M, Yarboroh CH, Takada K, Roebuck-Spencer T, Weickert T, et al. (2006) Anti-N-methyl-D-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. Arthritis Rheum 54: 2505–2514. https://doi.org/10.1002/art.22031 PMID: 16988971

13. Lawrence DA, Bolivar VJ, Hudson CA, Mondal TK, Pabello NG (2007) Antibody induction of lupus-like neuropsychiatric manifestations. J Neuroimmunol 182: 185–194. https://doi.org/10.1016/j.jneuroim.2006.10.017 PMID: 17156859

14. Stojanovich L, Zandman-Goddard G, Pavlovich S, Sikanich N (2007) Psychiatric manifestations in systemic lupus erythematosus. Autoimmun Rev 6: 421–426. PMID: 17537389

15. Postal M, Lapa AT, Sinicato NA, de Oliveira Pelicari K, Peres FA, Costallat LT, et al. (2016) Depressive symptoms are associated with tumor necrosis factor alpha in systemic lupus erythematosus. J Neuroinflammation 13: 5. https://doi.org/10.1186/s12974-015-0471-9 PMID: 26732584
16. Zonana-Nacach A, Roseman JM, McGwin G Jr., Friedman AW, Baethge BA, Reveille JD, et al. (2000) Systemic lupus erythematosus in three ethnic groups. VI: Factors associated with fatigue within 5 years of criteria diagnosis. LUMINA Study Group. LUpus in Minority populations: NATURE vs Nurture. Lupus 9: 101–109. PMID: 10787006

17. Ramsey-Goldman R, Rothrock N (2010) Fatigue in systemic lupus erythematosus and rheumatoid arthritis. PM R 2: 384–392. https://doi.org/10.1016/j.pmrj.2010.03.026 PMID: 20656619

18. Petri M, Kawata AK, Fernandes AW, Gajria K, Greth W, Hareendran A, et al. (2013) Impaired health status and the effect of pain and fatigue on functioning in clinical trial patients with systemic lupus erythematosus. J Rheumatol 40: 1865–1874. https://doi.org/10.3899/jrheum.130046 PMID: 24085548

19. Jump RL, Robinson ME, Armstrong AE, Barnes EV, Kilbourn KM, Richards HB (2005) Fatigue in systemic lupus erythematosus: contributions of disease activity, pain, depression, and perceived social support. J Rheumatol 32: 1699–1705. PMID: 16142863

20. Fonseca R, Bernardes M, Terroso G, de Sousa M, Figueiredo-Braga M (2014) Silent Burdens in Disease: Fatigue and Depression in SLE. Autoimmune Dis 2014: 790724. https://doi.org/10.1155/2014/790724 PMID: 24592329

21. Siemiatycki J (1979) A comparison of mail, telephone, and home interview strategies for household health surveys. Am J Public Health 69: 238–245. PMID: 420369

22. Rohde P, Lewinsohn PM, Seeley JR (1997) Comparability of telephone and face-to-face interviews in assessing axis I and II disorders. Am J Psychiatry 154: 1593–1598. https://doi.org/10.1176/ajp.154.11.1593 PMID: 9356570

23. Cohen BB, Vinson DC (1995) Retrospective self-report of alcohol consumption: test-retest reliability by telephone. Alcohol Clin Exp Res 19: 1156–1161. PMID: 8561285

24. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD (1989) The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46: 1121–1123. PMID: 24085548

25. Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67: 361–370. PMID: 6880820

26. Ferreira PL (2000) [Development of the Portuguese version of MOS SF-36. Part I. Cultural and linguistic adaptation]. Acta Med Port 13: 55–66. PMID: 11059056

27. Pais-Ribeiro J, Silva I, Ferreira T, Martins A, Meneses R, Baltar M (2007) Validation study of a Portuguese version of the Hospital Anxiety and Depression Scale. Psychol Health Med 12: 225–235; quiz 235–227. https://doi.org/10.1080/13548500500524088 PMID: 17365902

28. Marcolino JA, Suzuki FM, Alli LA, Gozzani JL, Mathias LA (2007) [Measurement of anxiety and depression in preoperative patients. Comparative study]. Rev Bras Anestesiol 57: 157–166. PMID: 19466349

29. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ (1989) The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 28: 193–213. PMID: 2748771

30. Carpenter JS, Andrykowski MA (1998) Psychometric evaluation of the Pittsburgh Sleep Quality Index. J Psychosom Res 45: 5–13. PMID: 9720850

31. Monck TH, Buysse DJ, Billy BD, Fletcher ME, Kennedy KS, Begley AE, et al. (2013) Shiftworkers report worse sleep than day workers, even in retirement. J Sleep Res 22: 201–208. https://doi.org/10.1111/jsr.12003 PMID: 23136831

32. Palmieri PA, Chipman KJ, Canetti D, Johnson RJ, Hobfoll SE (2010) Prevalence and correlates of sleep problems in adult Israeli Jews exposed to actual or threatened terrorist or rocket attacks. J Clin Sleep Med 6: 557–564. PMID: 21206544

33. Chalker T, Berelowitz G, Pawlikowska T, Watts L, Wessely S, Wright D, et al. (1993) Development of a fatigue scale. J Psychosom Res 37: 147–153. PMID: 8463991

34. Ware JE Jr., Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30: 473–483. PMID: 1599314

35. Funk JL, Rogge RD (2007) Testing the ruler with item response theory: increasing precision of measurement for relationship satisfaction with the Couples Satisfaction Index. J Fam Psychol 21: 572–583. https://doi.org/10.1037/0893-3200.21.4.572 PMID: 18179329

36. HS S. (1988) A generic measure of relationship satisfaction. Journal of Marriage and the Family 50: 93–98.

37. Zhang L, Fu T, Yin R, Zhang Q, Shen B (2017) Prevalence of depression and anxiety in systemic lupus erythematosus: a systematic review and meta-analysis. BMC Psychiatry 17: 70. https://doi.org/10.1186/s12888-017-1234-1 PMID: 28196529
38. Figueiredo-Braga M, Mota-Garcia F, O’Connor JE, Garcia JR, Mota-Cardoso R, Cardoso CS, et al. (2009) Cytokines and anxiety in systemic lupus erythematosus (SLE) patients not receiving antidepressant medication: a little-explored frontier and some of its brief history. Ann N Y Acad Sci 1173: 286–291. https://doi.org/10.1111/j.1749-6632.2009.04647.x PMID: 19758164

39. van Exel E, Jacobs J, Korswagen LA, Voskuyl AE, Stek M, Dekker J, et al. (2013) Depression in systemic lupus erythematosus, dependent on or independent of severity of disease. Lupus 22: 1462–1469. https://doi.org/10.1177/0961203313508443 PMID: 24135079

40. Morris G, Berk M, Galecki P, Walder K, Maes M (2016) The Neuro-Immune Pathophysiology of Central and Peripheral Fatigue in Systemic Immune-Inflammatory and Neuro-Imune Diseases. Mol Neurobiol 53: 1195–1219. https://doi.org/10.1007/s12035-015-9090-9 PMID: 25598355

41. Wiseman SJ, Bastin ME, Hamilton IF, Hunt D, Ritchie SJ, Amft EN, et al. (2017) Fatigue and cognitive function in systemic lupus erythematosus: associations with white matter microstructural damage. A diffusion tensor MRI study and meta-analysis. Lupus 26: 588–597. https://doi.org/10.1177/0961203316668417 PMID: 27667026

42. Inoue M, Shiozawa K, Yoshihara R, Yamane T, Shima Y, Hirano T, et al. (2017) Predictors of poor sleep quality in patients with systemic lupus erythematosus. Clin Rheumatol 36: 1053–1062. https://doi.org/10.1007/s10067-017-3545-5 PMID: 28138857

43. Mak A, Tang CS, Ho RC (2013) Serum tumour necrosis factor-alpha is associated with poor health-related quality of life and depressive symptoms in patients with systemic lupus erythematosus. Lupus 22: 254–261. https://doi.org/10.1177/0961203312471872 PMID: 23334278

44. Karol DE, Criscione-Schreiber LG, Lin M, Clowse ME (2013) Depressive symptoms and associated factors in systemic lupus erythematosus. Psychosomatics 54: 443–450. https://doi.org/10.1016/j.psym.2012.09.004 PMID: 23274009

45. Xie X, Wu D, Chen H (2016) Prevalence and risk factors of anxiety and depression in patients with systemic lupus erythematosus in Southwest China. Rheumatol Int 36: 1705–1710. https://doi.org/10.1007/s00296-016-3559-3 PMID: 27580610

46. Alexander JJ, Jacob A, Bao L, Macdonald RL, Quigg RJ (2005) Complement-dependent apoptosis and inflammatory gene changes in murine lupus cerebritis. J Immunol 175: 8312–8319. PMID: 16339572

47. Stock AD, Wen J, Puttermann C (2013) Neuropsychiatric Lupus, the Blood Brain Barrier, and the TWEAK/Fn14 Pathway. Front Immunol 4: 484. https://doi.org/10.3389/fimmu.2013.00484 PMID: 24400009

48. Manne S, Badr H (2010) Intimacy processes and psychological distress among couples coping with head and neck or lung cancers. Psychooncology 19: 941–954. https://doi.org/10.1002/pon.1645 PMID: 19885852

49. Lin EH, Katon W, Von Korff M, Tang L, Williams JW Jr., Kroenke K, et al. (2003) Effect of improving depression care on pain and functional outcomes among older adults with arthritis: a randomized controlled trial. JAMA 290: 2428–2429. https://doi.org/10.1001/jama.290.18.2428 PMID: 14612479